ScienceOpen: research and publishing network

For Researchers

Search
Advanced search

0

views

    

0

recommends

0

shares

Record: found
Abstract: found
Article: found

Is Open Access

Serum levels of lipoprotein-associated phospholipase A2 are associated with coronary atherosclerotic plaque progression in diabetic and non-diabetic patients

research-article

Author(s): Shudong Zhang ¹ , Jiangang Wang ² , Shuai Chen ³ ^, ⁴ , Ying Zhang ¹ , Ruming He ¹ , Xiaoqun Wang ³ ^, ⁴ , Fenghua Ding ³ ^, ⁴ , Wenbo Hu ⁵ , Yang Dai ³ ^, ⁴ , Lin Lu ³ ^, ⁴ , Ruiyan Zhang ³ ^, ⁴ , Jingwei Ni ¹ ^, ³ ^, , Qiujing Chen ³ ^, ⁴ ^,

Publication date (Electronic): 14 May 2024

Journal: BMC Cardiovascular Disorders

Publisher: BioMed Central

Keywords: Lp-PLA2, Type 2 diabetes mellitus, Plaque progression

Read this article at

ScienceOpen Publisher PMC

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

Lp-PLA2 is linked to cardiovascular diseases and poor outcomes, especially in diabetes, as it functions as a pro-inflammatory and oxidative mediator.

Objectives

This research aimed to explore if there is a connection between the serum levels of Lp-PLA2 and the progression of coronary plaques (PP) in individuals with type 2 diabetes mellitus (T2DM) and those without the condition.

Materials and methods

Serum Lp-PLA2 levels were measured in 137 T2DM patients with PP and 137 T2DM patients with no PP, and in 205 non-diabetic patients with PP and 205 non-diabetic patients with no PP. These individuals met the criteria for eligibility and underwent quantitative coronary angiography at the outset and again after about one year of follow-up. The attributes and parameters of the participants at the outset were recorded.

Results

Increased serum levels of Lp-PLA2 were closely associated with coronary artery PP, and also significantly correlated with change of MLD, change of diameter stenosis and change of cumulative coronary obstruction in both diabetic and non-diabetic groups, with higher correlation coefficients in diabetic patients as compared with non-diabetic patients. Moreover, multivariate logistic regression analysis showed that serum Lp-PLA2 level was an independent determinant of PP in both groups, with OR values more significant in diabetic patients than in non-diabetic patients.

Conclusions

Levels of serum Lp-PLA2 show a significant association with the progression of coronary atherosclerotic plaque in patients with T2DM and those without, especially among individuals with diabetes.

Related collections

Most cited references 34

Record: found
Abstract: found
Article: not found

A new equation to estimate glomerular filtration rate.

Andrew Levey, Lesley Stevens, Christopher H Schmid … (2009)

Equations to estimate glomerular filtration rate (GFR) are routinely used to assess kidney function. Current equations have limited precision and systematically underestimate measured GFR at higher values. To develop a new estimating equation for GFR: the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Cross-sectional analysis with separate pooled data sets for equation development and validation and a representative sample of the U.S. population for prevalence estimates. Research studies and clinical populations ("studies") with measured GFR and NHANES (National Health and Nutrition Examination Survey), 1999 to 2006. 8254 participants in 10 studies (equation development data set) and 3896 participants in 16 studies (validation data set). Prevalence estimates were based on 16,032 participants in NHANES. GFR, measured as the clearance of exogenous filtration markers (iothalamate in the development data set; iothalamate and other markers in the validation data set), and linear regression to estimate the logarithm of measured GFR from standardized creatinine levels, sex, race, and age. In the validation data set, the CKD-EPI equation performed better than the Modification of Diet in Renal Disease Study equation, especially at higher GFR (P < 0.001 for all subsequent comparisons), with less bias (median difference between measured and estimated GFR, 2.5 vs. 5.5 mL/min per 1.73 m(2)), improved precision (interquartile range [IQR] of the differences, 16.6 vs. 18.3 mL/min per 1.73 m(2)), and greater accuracy (percentage of estimated GFR within 30% of measured GFR, 84.1% vs. 80.6%). In NHANES, the median estimated GFR was 94.5 mL/min per 1.73 m(2) (IQR, 79.7 to 108.1) vs. 85.0 (IQR, 72.9 to 98.5) mL/min per 1.73 m(2), and the prevalence of chronic kidney disease was 11.5% (95% CI, 10.6% to 12.4%) versus 13.1% (CI, 12.1% to 14.0%). The sample contained a limited number of elderly people and racial and ethnic minorities with measured GFR. The CKD-EPI creatinine equation is more accurate than the Modification of Diet in Renal Disease Study equation and could replace it for routine clinical use. National Institute of Diabetes and Digestive and Kidney Diseases.

0 comments Cited 5082 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021

(2020)

The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

0 comments Cited 1052 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

Immunity and Inflammation in Atherosclerosis.

Dennis Wolf, Klaus Ley (2019)

There is now overwhelming experimental and clinical evidence that atherosclerosis is a chronic inflammatory disease. Lessons from genome-wide association studies, advanced in vivo imaging techniques, transgenic lineage tracing mice, and clinical interventional studies have shown that both innate and adaptive immune mechanisms can accelerate or curb atherosclerosis. Here, we summarize and discuss the pathogenesis of atherosclerosis with a focus on adaptive immunity. We discuss some limitations of animal models and the need for models that are tailored to better translate to human atherosclerosis and ultimately progress in prevention and treatment.

0 comments Cited 558 times – based on 0 reviews      Review now

Author and article information

Contributors

Jingwei Ni: njw11450@rjh.com.cn

Qiujing Chen: cqj40575@rjh.com.cn

Journal

Journal ID (nlm-ta): BMC Cardiovasc Disord

Journal ID (iso-abbrev): BMC Cardiovasc Disord

Title: BMC Cardiovascular Disorders

Publisher: BioMed Central (London )

ISSN (Electronic): 1471-2261

Publication date (Electronic): 14 May 2024

Publication date PMC-release: 14 May 2024

Publication date Collection: 2024

Volume: 24

Electronic Location Identifier: 251

Affiliations

[1 ]Department of Cardiovascular Medicine, Wuxi branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, ( https://ror.org/0220qvk04) Wuxi, China

[2 ]GRID grid.216417.7, ISNI 0000 0001 0379 7164, Health Management Medicine Center, the Third Xiangya Hospital, , Central South University, ; Changsha, China

[3 ]GRID grid.412277.5, ISNI 0000 0004 1760 6738, Department of Cardiovascular Medicine, , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, ; 197 Ruijin Road II, Shanghai, 200025 China

[4 ]Institute of Cardiovascular Diseases, Shanghai Jiao Tong University School of Medicine, ( https://ror.org/0220qvk04) Shanghai, China

[5 ]Eachy biopharma, Zhangjiagang, Jiangsu Province China

Article

Publisher ID: 3931

DOI: 10.1186/s12872-024-03931-x

PMC ID: 11092249

SO-VID: a59bbdaf-30a6-4e41-b792-7c367a400e40

Copyright © © The Author(s) 2024

License:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

History

Date received : 19 January 2024

Date accepted : 8 May 2024

Funding

Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;

Award ID: 82070358

Categories

Subject: Research

Custom metadata

issue-copyright-statement © BioMed Central Ltd., part of Springer Nature 2024

ScienceOpen disciplines: Cardiovascular Medicine

Keywords: lp-pla2,type 2 diabetes mellitus,plaque progression

Data availability:

ScienceOpen disciplines: Cardiovascular Medicine

Keywords: lp-pla2, type 2 diabetes mellitus, plaque progression

Comments

Comment on this article